This Article
Right arrow Full Text (PDF) Free
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Sign up for keyword alerts
Google Scholar
Right arrow Articles by McLeay, J. F.
Right arrow Articles by Walske, B. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by McLeay, J. F.
Right arrow Articles by Walske, B. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Facebook   Add to Technorati   Add to Twitter  
What's this?
Journal of Bone and Joint Surgery, 1960;42:940-944.
© 1960 by The Journal of Bone and Joint Surgery, Inc

Tetracycline Fluorescence in Bone Lesions

Preoperative Tetracycline Administration for the Identification of Abnormal Tissue during Operation and Tetracycline Concentration in Certain Bone Lesions

John F. McLeay M.D.1 and Benedict R. Walske M.D.1

1 Department of Surgery, Creighton University School of Medicine, Omaha

Tetracycline, administered intravenously, in divided doses of fifteen milligrams per kilogram of body weight per day for three or more days before operation, is deposited in bone lesions in such concentration that the malignant tissue will exhibit brilliant-yellow fluorescence under ultraviolet light in the operating room. This fluorescence can, therefore, be used in the detection and location of malignant tissue.

Rapidly growing bone also concentrates the tetracycline, but to a lesser degree.

In the malignant lesions that were studied in this series, the concentration of tetracycline was approximately six-fold greater than that in normal new bone. After the tetracycline is in the bone it maintains its fluorescence and bacteriostatic activity up to six months in specimens kept at - 10 degrees centigrade.

Tetracycline combined with radioactive iodine (I-131) may prove to be of diagnostic and therapeutic value for neoplasms, especially malignant conditions of bone.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Facebook Facebook   Add to Technorati Technorati   Add to Twitter Twitter    What's this?